

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27768

Title: Usefulness of vonoprazan, a potassium ion-competitive acid blocker (P-CAB), for primary eradication of *Helicobacter pylori*.

Reviewer's code: 02533618

Reviewer's country: Turkey

Science editor: Ya-Juan Ma

Date sent for review: 2016-06-17 09:49

Date reviewed: 2016-06-30 16:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

1. As this is a new drug and waiting for approval, and also still the phase trials are going on, more detailed information regarding the mechanism of action, possible toxic effects and the adverse drug reactions that have been observed should be indicated. 2. Please indicate the doses that the patients received and if the doses alter between the groups please evaluate the results according to that. 3. If exists, please indicate the strains of the *H. pylori* and discuss the effectiveness of the treatment according to these subgroups.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27768

Title: Usefulness of vonoprazan, a potassium ion-competitive acid blocker (P-CAB), for primary eradication of *Helicobacter pylori*.

Reviewer's code: 00503623

Reviewer's country: United States

Science editor: Ya-Juan Ma

Date sent for review: 2016-06-17 09:49

Date reviewed: 2016-07-02 01:39

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript reports on the efficacy of potassium ion-competitive acid blocker, vonoprazan, therapy for Hp eradication. The authors have analyzed the Hp primary eradication data of 2507 and that of 452 patients undergoing secondary eradication. The results revealed that vonoprazan group achieved a significantly higher eradication rate than that of PPI group. In particular, the much eradication rate was observed in patients with chronic gastritis, and younger patients. However, there was no difference in the eradication rates between vonoprazan and PPI groups in patients undergoing secondary Hp eradication therapy. Hence, the authors concluded that vonoprazan therapy for Hp eradication may be advantageous over that utilizing PPIs. The paper is well written, and the possible advantageous mechanism of vonoprazan action is adequately explored in the Discussion. Therefore, the paper should be of interest to the readership of the Journal. Good Job !

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27768

Title: Usefulness of vonoprazan, a potassium ion-competitive acid blocker (P-CAB), for primary eradication of *Helicobacter pylori*.

Reviewer's code: 03009708

Reviewer's country: Iran

Science editor: Ya-Juan Ma

Date sent for review: 2016-06-17 09:49

Date reviewed: 2016-07-02 13:15

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Interesting paper but should make some sort of revision before publishing. Better abstract is necessary. Some typos were observed. 1- Reference style is not according to the journal format. 2- This can be a short communication rather than original paper. 3- Introduction should be shortened.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27768

Title: Usefulness of vonoprazan, a potassium ion-competitive acid blocker (P-CAB), for primary eradication of Helicobacter pylori.

Reviewer's code: 00183433

Reviewer's country: Iran

Science editor: Ya-Juan Ma

Date sent for review: 2016-06-17 09:49

Date reviewed: 2016-07-02 16:58

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

1-Description of vonoprazan, its priorities to proton pump inhibitors, and the mechanism of its inhibitory action on H.pylori must be included in the manuscript. Furthermore, it is not clear whether authors used vonoprazan alone or in combination with antibiotics and bismuth. 2-Methods must be described in more details, clear and precise. 3-The number of patients in each group tested by different diagnostic methods must be mentioned. 4- Authors mentioned that vonoprazan eradicates H.pylori. They should explain how. How did they confirm eradication of H.pylori infection. They mentioned that eradication was confirmed by UBT. It is noteworthy that results of several studies have indicated that proton pump inhibitors exert inhibitory effect on H.pylori urease activity but do not kill the bacterium. Accordingly, authors must consider the likelihood of inhibitory effect of vonoprazan on H.pylori urease activity and false negative results of UBT and specially be careful when mentioning eradication. 6- The aim of study is confusing. According to what has been mentioned at the end of introduction, the aim of study is to show that vonoprazan alone could eradicate H.pylori infection which is not clear

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27768

Title: Usefulness of vonoprazan, a potassium ion-competitive acid blocker (P-CAB), for primary eradication of *Helicobacter pylori*.

Reviewer's code: 00035741

Reviewer's country: Japan

Science editor: Ya-Juan Ma

Date sent for review: 2016-06-17 09:49

Date reviewed: 2016-07-05 15:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript describes the comparison of eradication rates between vonoprazan containing regimen and other PPI containing regimen. Some issues to improve this paper are listed below.

1. Were there any patients enrolled in this study who were checked drug resistances against antimicrobials? Eradication rates should be shown according to status of drug susceptibilities.
2. Adverse events should be demonstrated with a Table.
3. In the first-line therapy, eradication rate of vonoprazan group is superior to that of other PPI group. But in second-line therapy almost the same in the eradication rate in spite of the stronger anti-acid effect of vonoprazan. Authors should discuss about it.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 27768

Title: Usefulness of vonoprazan, a potassium ion-competitive acid blocker (P-CAB), for primary eradication of Helicobacter pylori.

Reviewer's code: 00011429

Reviewer's country: Turkey

Science editor: Ya-Juan Ma

Date sent for review: 2016-06-17 09:49

Date reviewed: 2016-07-14 05:19

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is a retrospective study comparing vonoprazan, a potassium ion-competitive acid blocker (P-CAB) to conventional triple therapy for the eradication of H. pylori. The success of triple therapy is getting decrease in recent years for the eradication of H. pylori, and new treatment regimens are urgently needed. In this context, this is an interesting study with a new acid inhibitor drug. However, there are some major problems about the method and interpretation of the results. 1.Vonoprazan is a new drug which probably many readers are not familiar. What is the exact mechanisms and why they are superior to PPIs for acid inhibitory effect. 2.The inhibition of acid secretion is important for the eradication however the major determinant of the eradication success is the effect of antibiotics, and antibiotics resistance. The major problem with conventional triple regimens are increasing antibiotic resistance. How vonoprazan overcome this resistance? 3.We do not have any detailed information in Vonoprazon group? Which antibiotics did they receive? 4.There are a huge difference between the numbers of the patients between two groups which can affect statistical comparisons. 5. The retrospective and non-randomized design of the study limits the value



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

of the study significantly. A randomized controlled study is needed to show the true effectiveness of this new drug.